pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,998 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1561Endpoints1219BioSpace560Fierce Biotech556BioPharma Dive464raps192onclive165fda recalls102
therapy area
allOncology10376Rare Disease2719Immunology2442Cardiology2281Hematology1880Pulmonology1872Vaccines
  • 2026 Nobel Prize awarded to U.S. and German scientists for optogenetics breakthroughs
    The 2026 Nobel Prize in Physiology or Medicine was awarded to three researchers for their pioneering work on optogenetics. The laureates-Karl Deisseroth of Stanford University and the Howard Hughe…
    STAT · 16d agoNeutral↗ source
  • Genentech pays Alector $100M for preclinical Parkinson’s prospect
    Genentech is paying Alector $100 million upfront for exclusive rights to a preclinical drug candidate that targets a driver of neurodegeneration in Parkinson’s disease.
    Fierce Biotech · 16d agoDealNeutral↗ source
← prev
page 20 of 160
next →
fda medwatch93
globenewswire health73
fda press54
1641
Psychiatry & CNS1107
Ophthalmology849
Endocrinology & Metabolism687
Pain654
Nephrology634
  • Stem cell advocates anticipate FDA roundtables as peptide therapies gain regulatory foothold
    At PepMed 2026, a conference focused on peptide medicines, stem cell entrepreneur Chuck Meeker said he expects the FDA to hold a series of roundtables on regenerative therapies before year‑end. He…
    STAT · 16d agoRegulatoryNeutral↗ source
  • Swiss CDMOs and CROs experience rapid growth as global sponsors seek specialized manufacturing and decentralized trials
    Switzerland’s contract development and manufacturing organisations (CDMOs) and contract research organisations (CROs) are entering a new boom cycle, driven by rising global demand for specialised m…
    BioSpace · 16d agoDealPositive↗ source
  • Staggering health insurance premiums force employers to rethink coverage options
    Employers are confronting staggeringly high health insurance premiums, according to a STAT+ newsletter by reporter Bob Herman. The piece highlights how rising costs are forcing some businesses to r…
    STAT · 15d agoNegative↗ source
  • Will AI like Claude ever earn a Nobel Prize in medicine?
    Jeffrey S. Flier, a distinguished professor at Harvard and former dean of Harvard Medical School, writes an opinion piece prompted by the recent Nobel announcement. He asks whether an artificial-in…
    STAT · 16d agoNeutral↗ source
  • Mimetic Medicines' peptide reduces pain-related sodium channels in mice, offering new neuropathic pain strategy
    Researchers at Mimetic Medicines tested a short lipidated peptide (SLiP) in mice and found it lowered the presence of Nav1.8 sodium channels on sensory neuron membranes. Reducing these channels hel…
    Fierce Biotech · 15d agoPositive readoutPositive↗ source
  • Federal Appeals Judges Reject HHS Arguments in Humana Medicare Advantage Audit Lawsuit
    Federal appeals judges on Monday rebuked the Health and Human Services Department's arguments in a hearing on Humana's lawsuit challenging a new Medicare Advantage audit rule. Humana, the nation's…
    STAT · 15d agoRegulatoryNeutral↗ source
  • Genentech parts ways with global AI head Richard Bonneau
    Genentech, the Roche biotech unit, announced that its global head of artificial intelligence for drug discovery, computational biologist Richard Bonneau, has left the company effective immediately.…
    Endpoints · 15d agoNegative↗ source
  • Two Massachusetts biotech firms shut down, ending cancer and eye‑disease programs
    Adecto Pharmaceuticals, a Boston‑based biotech developing a treatment for cancers resistant to standard immunotherapy, announced it has ceased operations as of September 30. CEO Nora Minerva shared…
    BioSpace · 15d agoNegative↗ source
  • Report highlights 20 women reshaping biopharma across oncology and rare disease fields
    The 2026 special report spotlights twenty women who are driving change in biopharma, covering areas such as oncology and rare diseases. The series, now in its eighth year, has recognized over 160…
    Endpoints · 15d agoPositive↗ source
  • Energy drinks partner with college sports, raising safety concerns for teens
    Kent Sepkowitz, a professor emeritus at Weill‑Cornell Medical College, writes that energy drinks have grown into an $85‑billion global market and are now being marketed alongside college sports pro…
    STAT · 16d agoNegative↗ source
  • Weighing the risks of CAR T in autoimmune disease as Kyverna nears market
    Not a month after reports of three deaths in autoimmune trials for Novartis' CAR T cell therapy ignited a debate about the use of these treatments in nonfatal diseases, Kyverna Therapeutics reporte…
    BioSpace · 16d ago↗ source
  • Trump pledges $90 one-time Medicare Part B premium payment to over 20 million seniors before midterms
    President Donald Trump announced on social media that more than 20 million Medicare Part B enrollees will receive a one-time $90 payment to help cover their premiums. The promise comes days before…
    STAT · 16d agoNeutral↗ source
  • Eli Lilly reports strongest weight-loss data yet; Sanofi and Regeneron secure $1 billion upfront deal
    The weekly Endpoints newsletter dated October 3, 2026 highlights that Eli Lilly's latest weight‑loss trial produced its best‑ever results. While the article does not provide specific numbers, the…
    Endpoints · 18d agoDealNeutral↗ source
  • Novartis signs $7.8 billion deal with Abogen for mRNA-encoded autoimmune T-cell engager
    Novartis announced it will pay $575 million upfront to Abogen Biosciences for an mRNA-encoded T-cell engager that has shown early clinical activity in autoimmune disease. The agreement includes up…
    Fierce Biotech · 19d agoDealNeutral↗ source
  • BMO sees Merck better positioned than BMS to handle looming patent cliffs
    BMO Capital Markets says Merck has a stronger plan than Bristol Myers Squibb to replace revenue lost to upcoming patent expirations. The firm highlights Merck's pipeline as more derisked and sizabl…
    BioSpace · 18d agoNeutral↗ source
  • Pennsylvania reports fifth measles death as outbreak expands
    A recent report notes that Pennsylvania has recorded its fifth death linked to measles, underscoring the seriousness of the current outbreak in the state. Health officials are tracking the spread,…
    STAT · 19d agoNegative↗ source
  • Xaira Therapeutics details its generative AI antibody platform X-Design and unveils first pipeline candidates
    Xaira Therapeutics, which raised $1 billion in 2024, has now shared details of its AI-driven antibody design platform called X-Design and provided a glimpse of its emerging pipeline. The company s…
    Fierce Biotech · 19d agoPositive↗ source
  • Novartis pays $575 million upfront for worldwide rights to Abogen’s CD19xCD3 mRNA T-cell engager
    Novartis announced it will pay Abogen Biosciences $575 million upfront for exclusive worldwide rights to its lead early‑stage CD19xCD3 mRNA T‑cell engager. The agreement gives Novartis access to t…
    Endpoints · 19d agoDealPositive↗ source
  • Bayer outlines $2.2 billion Ohio plant that will add roughly 600 jobs
    Bayer announced its plan for a new manufacturing complex in New Albany, Ohio, with an investment of about $2.2 billion. The facility is expected to create roughly 600 new jobs in the region, suppo…
    Endpoints · 18d agoPositive↗ source
  • Aviceda Therapeutics to wind down after Phase 2 failure in geographic atrophy program
    Aviceda Therapeutics, a biotech focused on geographic atrophy, announced it is winding down operations. The decision follows a Phase 2 trial that did not meet its endpoints, halting plans to move…
    Endpoints · 18d agoNegative↗ source
  • FDA launches new office in CDER to modernize clinical trials
    The FDA announced the creation of a new office within its Center for Drug Evaluation and Research (CDER) dedicated to modernizing clinical trials. The office aims to accelerate the design and exec…
    Endpoints · 18d agoRegulatoryNeutral↗ source
  • Eli Lilly signals entry into aesthetics market with plans to acquire skin, body and hair treatments
    Eli Lilly is indicating an interest in expanding into the aesthetics sector, according to a recent job posting. The company appears to be seeking opportunities to add products that address skin agi…
    Endpoints · 18d agoNeutral↗ source
  • Study finds modest rise in youth opioid medication use but declining six-month retention
    Researchers examined Medicaid and insurance claims for Americans aged 13 to 25 diagnosed with opioid use disorder between 2016 and 2023. The analysis, published in JAMA Network Open, aimed to asses…
    STAT · 18d agoNeutral↗ source